Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT00574132
First received: December 10, 2007
Last updated: October 30, 2013
Last verified: October 2013